Ligand Pharmaceuticals Incorporated
LGNDHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Ligand Pharmaceuticals Incorporated (LGND) is listed under Biotechnology. With a market capitalization of $6.05B, it sits in mid-cap territory. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Market Cap
$6.05B
Beta
1.01
P/E (TTM)
31.98
P/E (Fwd)
25.40
EPS (TTM)
$9.49
EPS (Fwd)
$11.95
ROE
22.0%
ROA
4.0%
Cash
$1.36B
Total Debt
$1.13B
Free CF
$139.7M
52W Change
59.8%
Annual Financials
Cash vs Debt
Where LGND stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, LGND finished 12.03% above its 150-day moving average ($263.81) and 19.68% above its 200-day moving average ($246.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LGND overbought or oversold?
At the October 19, 2026 close, LGND's RSI(14) was 37.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $1.36B in cash and $1.13B in debt, LGND maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $139.7M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 22.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $196.2M (2022) to $268.1M (2025), reflecting a 37% increase over the period.
Investors considering Ligand Pharmaceuticals Incorporated should weigh the typical risks associated with LGND's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ligand Pharmaceuticals Incorporated's trajectory.